Lineage Cell Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $3,779 | $1,408 | $1,444 | $2,088 |
Gross Profit | 3,741 | 1,364 | 1,171 | 1,657 |
EBITDA | -3,699 | -5,725 | -6,486 | -4,539 |
EBIT | -3,840 | -5,867 | -6,661 | -4,714 |
Net Income | -3,034 | -5,760 | -6,542 | -4,775 |
Net Change In Cash | 3,779 | 1,408 | 1,444 | 2,088 |
Free Cash Flow | -5,699 | -5,226 | -5,821 | -6,110 |
Cash | 27,750 | 29,622 | 43,576 | 35,442 |
Basic Shares | 188,835 | 188,813 | 182,909 | 172,663 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $8,945 | $14,703 | $3,896 | $773 |
Gross Profit | 8,274 | 13,975 | 2,470 | 388 |
EBITDA | -24,041 | -21,793 | -48,338 | -24,408 |
EBIT | -24,733 | -22,520 | -49,225 | -26,519 |
Net Income | -21,486 | -26,353 | -38,564 | -20,685 |
Net Change In Cash | 8,945 | 14,703 | 3,896 | 773 |
Cost of Revenue | -43,468 | 23,114 | 23,150 | |
Free Cash Flow | -29,240 | 646 | -23,915 | -19,817 |
Cash | 35,442 | 11,355 | 55,742 | 32,585 |
Basic Shares | 172,663 | 169,792 | 164,502 | 150,044 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.02 |
2024-06-30 | -$0.03 |
2024-03-31 | -$0.04 |
2023-12-31 | -$0.03 |
